![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -0.69% | 71.50 | 71.00 | 72.00 | 72.00 | 70.00 | 72.00 | 1,276,183 | 16:20:34 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 23.25M | -24.95M | -0.0695 | -10.29 | 258.51M |
Date | Subject | Author | Discuss |
---|---|---|---|
22/5/2024 16:54 | Aman - Smith did not have a hand in developing the IP, scientist yes, innovator/research genius, no. As for his ability to lead a commercial organisation through the minefield of a startup (which it still remains, after so many years)? Soul of the company - IMHO, no. I share your concerns and watch with interest as to whether the science comes to the fore again - after the longest P1 trial in recent history, we are all still waiting in hope. Currently out (yes, with a loss , eyes fully dried) but could buy back in if the new girl turns out to be a good one and takes this company by the scruff of the neck, starts to close out trials in UK/US with dates and objectives met. Given the Convi, and limited cash /high expense levels, there remains the prospect of a big fall (hence the exit)and the potential for a fire-sale that leaves current LTH’s sitting on toilet paper - which will be a great shame for the company and investors trapped. So the new girl needs to navigate carefully on the next Convi payment - all eyes on how that gets settled - big call! | stmcn | |
22/5/2024 15:58 | Silence is never good. Possibility of carnage inbound. It.s too quiet, way too quiet. New ceo might put out a fluffer rns for you. I.m waiting. Smith gone - the soul has gone. | ![]() amanitaangelicus | |
22/5/2024 10:40 | Going blue ummm | ![]() bobaxe1 | |
22/5/2024 10:13 | Tom that is what worries me mkt cap 115m yet it's not worth anywhere near that currently. Drugs are a long way off ever seeing the money the rest of the business looks average at best and not generating a profit either. Expect to see this head a lot lower from here unless they can pull a rabbit out of the hat which seems unlikely from here | ![]() bones698 | |
22/5/2024 09:17 | I can't believe this company still has a market cap over 100m ffs Surely if the tech was that good people would be scrambling over this company lol | tomzimerman | |
22/5/2024 08:46 | fieldhouse - "Very disillusioned, it seems that the TW supporters were correct." Please have some respect. I for one was not a supporter of TW regarding AVCT. It was clear to me since joining the thread they were lying about the world beating LFT and AVA6000. Furthermore recent events regarding the Post Office Horizon and infected blood scandals show the lengths companies, organisations and individuals will go to in order to protect their income and reputations. JakNife - None of the so called guided missiles are as effective as DOX in killing cancer cells. The problem with DOX is its toxicity. The Holy Grail for cancer is still to be able to deliver DOX without its toxicity. | ![]() pwhite73 | |
21/5/2024 23:07 | https://www.theguard | ![]() wilmer100 | |
21/5/2024 17:56 | Very disillusioned, it seems that the TW supporters were correct. Decided to cut my losses an over the last two months. Still have a small holding . Switched money into Hochschild mining shares !, They are up 30% so mitigating some losses. What a shambles! | ![]() fieldhouse | |
21/5/2024 16:15 | Worryingly the mkt cap is 118m still. Any more bad news and this does look likely to fall heavily. Selling the diagnostic division might help a bit but I doubt it will realise the value they think it's worth and end up keeping hold of it. Saying as that's what generates the revenue mainly here it's hard to see what they can do to stop this getting a lot worse. Biotechs are simply not a good place to be right now especially ones a long way from the promised land | ![]() bones698 | |
21/5/2024 14:02 | Goforgold ...i.d missed out that this was a French comp. Thnx for your erudite comments. Slip sliding away ...Simon and Garfunkel. What the hell has caused Smith to gan? Big question - where s Myles when you need a boost? | ![]() amanitaangelicus | |
21/5/2024 12:19 | FAIL FAIL 99% FAIL FAIL 99% FAIL FAIL 99% FAIL FAIL 99% FAIL FAIL 99% FAIL FAIL 99% FAIL FAIL 99% FAIL FAIL 99% FAIL FAIL | ![]() goforgold1 | |
21/5/2024 12:19 | How much have they raised lol over the years they did not even get a Covid vaccine out ha ha . 99% FAIL FAIL 99% FAIL FAIL 99% FAIL FAIL 99% FAIL FAIL 99% FAIL FAIL 99% FAIL FAIL 99% FAIL FAIL 99% FAIL FAIL 99% FAIL FAIL | ![]() goforgold1 | |
21/5/2024 12:17 | Scam of the year this will end up. SCAM SCAM SCAM SCAM SCAM . Just waiting for the RNS to confirm it 99% fail and you think this is the 1 percent to achieve . Plus it's a French company says it all. | ![]() goforgold1 | |
21/5/2024 07:19 | Yes with the death spiral loan conversions I don't see the share price going anywhere but down, with the odd spike to forward sell it. The Diagnostics story has been a total debacle from beginning to end, Affimers are going nowehere after years of little but empty promises, so pretty much all they are left with are two drugs that others failed to commercialise, one of which is going for the Guinness book of records for a Phase 1 trial and the other hasn't even got that far. They don't have enough funds for any Phase 2 trials anyway. Best hope now is a white knight who will fund them to market, if they can ever get that far (but who will take a big slice) but I've seen no sign of any so far. In fact it's been so bad that they've even had to throw the Wetherby Waffler overboard. | 1347 | |
20/5/2024 20:35 | Looks like the diagnostic division will either be floated or sold. Unfortunately now is not the best time for either with the amount likely to be realised far lower than they would like and unlikely to provide the good news needed. AV6000 whilst promising is a very long way off and an expensive road. They have just over a years cash after the recent raise. Mkt cap 127m looks very exoecnsive for something heavily loss making and. Along way from any major success with a lot of risks along the way. I expect to see this continue to fall further as its currently at a cross roads with changes and decidimg which way they want to go. Whatever they are currently doing isn't working. The affirmer micro array looks like it' has a long way to go before being a viable product lack of clinical data etc Worth 15-20p maybe at this stage imo | ![]() bones698 | |
20/5/2024 07:28 | Good morning and welcome to Series 3 of the Avactatons. Who will triumph? Who will be declared the Diamond? Where has the family Smith gone? Has dishonour struck? What skullduggery has been unearthed? Did Myles and Tickboo manage to find the perfect dresses for the big leaving bash? All will be revealed soon I.m sure. Tick Tock. Tick Tock. All.s fair in love and war ...Yours humblyLady Whistledown. | ![]() amanitaangelicus | |
19/5/2024 22:23 | 20p or there about is bang on for me | hamidahamida | |
17/5/2024 16:45 | Very coiled ...so coiled it could spring either way. I repeat ...why has Smith left without a word? Gone! His baby left on the steps. He.s nurtured the brat for eons , then he leaves without a word. Something.s happened for sure, but what? I fear the worse. Aim has a nasty habit of gutting the unwary. Chin chin fillet knife anyone? | ![]() amanitaangelicus | |
17/5/2024 10:42 | It's a tension spring though.! | ![]() filthypoor |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions